{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:32:55Z","timestamp":1754195575195},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"Supplement_C","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hyperkalaemia is a life-threatening condition leading to significant morbidity and mortality. It is common in heart failure (HF) patients due to the disease itself, which often co-exists with chronic kidney disease and diabetes mellitus, the fluctuations in renal function, and the use of some drugs [i.e. renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors]. In particular, hyperkalaemia opposes to their administration or up-titration, thus impacting on mortality. New K+ binders, namely, patiromer and sodium zirconium cyclosilicate, are an intriguing option to manage hyperkalaemia in HF patients, both to reduce its fatal effects and to let clinicians up-titrate RAAS inhibitors. Even if their real impact on strong outcomes is still to be determined, we hereby provide an overview of hyperkalaemia in HF and its current management. New trials are welcome to fill the gap in knowledge.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad053","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T07:13:38Z","timestamp":1674890018000},"page":"C301-C305","source":"Crossref","is-referenced-by-count":1,"title":["In pursuit of balance: renin\u2013angiotensin\u2013aldosterone system inhibitors and hyperkalaemia treatment"],"prefix":"10.1093","volume":"25","author":[{"given":"Edoardo","family":"Sciatti","sequence":"first","affiliation":[{"name":"Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII , Piazza OMS 1, Bergamo 24127 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII , Piazza OMS 1, Bergamo 24127 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Balestrieri","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII , Piazza OMS 1, Bergamo 24127 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"D\u2019Isa","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII , Piazza OMS 1, Bergamo 24127 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Iacovoni","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII , Piazza OMS 1, Bergamo 24127 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII , Piazza OMS 1, Bergamo 24127 , Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca , Piazza dell'Ateneo Nuovo, 1, 20126 Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"2023091811281864300_suad053-B1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023091811281864300_suad053-B2","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"2023091811281864300_suad053-B3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Circulation"},{"key":"2023091811281864300_suad053-B4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2023091811281864300_suad053-B5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2023091811281864300_suad053-B6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2023091811281864300_suad053-B7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10557-018-6783-0","article-title":"Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies","volume":"32","author":"Hoppe","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023091811281864300_suad053-B8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2023091811281864300_suad053-B9","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1093\/eurheartj\/suy028","article-title":"Hyperkalaemia: aetiology, epidemiology, and clinical significance","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"2023091811281864300_suad053-B10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11897-009-0037-1","article-title":"Hyperkalemia in patients with heart failure: incidence, prevalence, and management","volume":"6","author":"Desai","year":"2009","journal-title":"Curr Heart Fail Rep"},{"key":"2023091811281864300_suad053-B11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2023091811281864300_suad053-B12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2023091811281864300_suad053-B13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B15","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023091811281864300_suad053-B16","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","article-title":"Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"30","author":"Raebel","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"2023091811281864300_suad053-B17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B18","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ejhf.2024","article-title":"Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study","volume":"22","author":"Volterrani","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B19","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B21","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI)","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2023091811281864300_suad053-B22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.jrn.2015.10.002","article-title":"Exploring problems in following the hemodialysis diet and their relation to energy and nutrient intakes: the BalanceWise study","volume":"26","author":"St-Jules","year":"2016","journal-title":"J Ren Nutr"},{"key":"2023091811281864300_suad053-B23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2023091811281864300_suad053-B24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2014.09.012","article-title":"Dietary and fluid restrictions in CKD: a thematic synthesis of patient views from qualitative studies","volume":"65","author":"Palmer","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2023091811281864300_suad053-B25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jhn.12483","article-title":"Integrating renal nutrition guidelines into daily family life: a qualitative exploration","volume":"31","author":"Morris","year":"2018","journal-title":"J Hum Nutr Diet"},{"key":"2023091811281864300_suad053-B26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jorc.12134","article-title":"The problematic world of following a renal diet outside the home","volume":"41","author":"Morris","year":"2015","journal-title":"J Ren Care"},{"key":"2023091811281864300_suad053-B27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1755-6686.2008.00034.x","article-title":"Facilitating dietary change in renal disease: investigating patients\u2019 perspectives","volume":"34","author":"Hollingdale","year":"2008","journal-title":"J Ren Care"},{"key":"2023091811281864300_suad053-B28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.jrn.2018.02.005","article-title":"Experiences and perspectives of dietary management among patients on hemodialysis: an interview study","volume":"28","author":"Stevenson","year":"2018","journal-title":"J Ren Nutr"},{"key":"2023091811281864300_suad053-B29","first-page":"1","article-title":"KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023091811281864300_suad053-B30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","journal-title":"Kidney Int"},{"key":"2023091811281864300_suad053-B31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2023091811281864300_suad053-B32","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023091811281864300_suad053-B33","doi-asserted-by":"crossref","first-page":"iii51","DOI":"10.1093\/ndt\/gfz213","article-title":"Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia","volume":"34","author":"Bianchi","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023091811281864300_suad053-B34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2016.07.032","article-title":"Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia","volume":"118","author":"Pitt","year":"2017","journal-title":"Pharmacol Res"},{"key":"2023091811281864300_suad053-B35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2023091811281864300_suad053-B36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/gfz150","article-title":"Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study","volume":"35","author":"Laureati","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2023091811281864300_suad053-B37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2023091811281864300_suad053-B38","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2023091811281864300_suad053-B39","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2023091811281864300_suad053-B40","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.3390\/jcm10235483","article-title":"Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: rapid review and meta-analysis","volume":"10","author":"Montagnani","year":"2021","journal-title":"J Clin Med"},{"key":"2023091811281864300_suad053-B41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000481270","article-title":"Patiromer lowers serum potassium when taken without food: comparison to dosing with food from an open-label, randomized, parallel group hyperkalemia study","volume":"46","author":"Pergola","year":"2017","journal-title":"Am J Nephrol"},{"key":"2023091811281864300_suad053-B42","doi-asserted-by":"crossref","first-page":"e2145236","DOI":"10.1001\/jamanetworkopen.2021.45236","article-title":"Assessment of patiromer monotherapy for hyperkalemia in an acute care setting","volume":"5","author":"Di Palo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023091811281864300_suad053-B43","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"2023091811281864300_suad053-B44","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B45","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"Zannad","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2023091811281864300_suad053-B46"},{"key":"2023091811281864300_suad053-B47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"2023091811281864300_suad053-B48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"2023091811281864300_suad053-B49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023091811281864300_suad053-B50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study","volume":"36","author":"Roger","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023091811281864300_suad053-B51","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/phar.1906","article-title":"Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia","volume":"37","author":"Meaney","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2023091811281864300_suad053-B52","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/DDDT.S143461","article-title":"Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate","volume":"11","author":"Zann","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2023091811281864300_suad053-B53","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023091811281864300_suad053-B54","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/ejhf.1987","article-title":"Serum potassium in the PARADIGM-HF trial","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2023091811281864300_suad053-B55","doi-asserted-by":"crossref","first-page":"106277","DOI":"10.1016\/j.phrs.2022.106277","article-title":"Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease","volume":"182","author":"Rossignol","year":"2022","journal-title":"Pharmacol Res"},{"key":"2023091811281864300_suad053-B56","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818777943","article-title":"Proton-pump inhibitors among adults: a nationwide drug-utilization study","volume":"11","author":"H\u00e1lfd\u00e1narson","year":"2018","journal-title":"Therap Adv Gastroenterol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_C\/C301\/51665474\/suad053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_C\/C301\/51665474\/suad053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T11:30:40Z","timestamp":1695036640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_C\/C301\/7143272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":56,"journal-issue":{"issue":"Supplement_C","published-online":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad053","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,4,26]]}}}